Local irresectable carcinoma of the pancreas was diagnosed by explorative laparotomy of a 62-years old patient. At this stage (T3 N1 M0), a curative surgical therapy was not possible. The prognosis in these cases is bad. Medium survival time is less than half a year. In order to improve prognosis a combined radiochemotherapy has been applied. The total tumor dose of 44.8 Gy was applied in 2 daily fractions of 1.6 Gy. On the first 3 days of radiotherapy 600 mg/m2 5-FU and 300 mg/m2 folinic acid were given i.v.. Chemotherapy was repeated each 28 days. After 45 months of observation and application of 20 courses chemotherapy no local or systemical progress can be proven in this patient. His health status is good. A combined radio-chemotherapy improves prognosis in locally irresectable carcinoma of the pancreas. In particular cases survival time is surprisingly long.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Local administration of immunotherapy for patients with skin cancer: A systematic review.
Cancer Treat Rev
December 2024
Department of Medical Oncology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address:
Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered.
View Article and Find Full Text PDFExtrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome.
JCO Precis Oncol
July 2024
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose: This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival.
Materials And Methods: Consecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival.
Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study.
Dis Esophagus
October 2024
Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Definitive chemoradiotherapy (dCRT) is a potentially curative therapy for esophageal cancer. As indications for dCRT differ widely, it is challenging to draw conclusions on outcomes and survival. The aim of this study was to evaluate overall survival (OS) and recurrence patterns according to indications for treatment.
View Article and Find Full Text PDFNational guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
World J Gastroenterol
March 2024
Department of Gastroenterology & Hepatology, Pakistan Kidney and Liver Institute & Research Centre, Lahore 54000, Pakistan.
Article Synopsis
- A consensus meeting of national hepatobiliary experts took place on May 26, 2023, at PKLI & RC, aiming to develop guidelines for managing hilar cholangiocarcinoma (hCCA).
- The meeting emphasized the need for a multidisciplinary approach to manage hCCA effectively, highlighting diagnostic methods like CT and MRI for staging, as well as the importance of surgical resection for potentially curative treatment.
- For patients with unresectable hCCA, options include liver transplantation and palliative chemotherapy, with guidelines suggesting personalized treatment plans based on local discussions.
Endoscopic resection for residual oesophageal neoplasia after definitive chemoradiotherapy.
Best Pract Res Clin Gastroenterol
February 2024
Department of Gastroenterology and Hepatology, Rotterdam MC Cancer Institute, University Medical Center Rotterdam, the Netherlands. Electronic address:
Definitive chemoradiation is the recommended treatment for locally advanced, irresectable oesophageal cancer and a valid alternative to neoadjuvant chemoradiotherapy (CRT) with surgery in oesophageal squamous cell cancer (OSCC) patients. In case of locoregional recurrence, salvage treatment can be considered in fit and resectable patients. Salvage surgery is a valid option but associated with significant morbidity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!